The Prostate and Urologic Cancer Research Group conducts and supports research on the prevention and early detection of prostate and bladder cancer. Clinical trials and the evaluation of new agents, surrogate biomarkers, and new technologies to identify premalignant lesions are developed and supported.
Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
Major medical research centers conduct systematic early clinical development of promising preventive agents.
Prostate Cancer Prevention and Finasteride: A Conversation with NCI’s Dr. Howard Parnes
In 2003, results from the Prostate Cancer Prevention Trial (PCPT)—an NCI-funded randomized clinical trial with nearly 19,000 participants—showed that men aged 55 and older who used the drug finasteride daily for 7 years had a substantially reduced risk of developing prostate cancerExit Disclaimer.